Recent research has indicated that the gut microbiota plays an important role in managing metabolic health. Disturbance of gut microbiota by a typical western lifestyle leads to changes in serum lipopolysaccharides, shortchain fatty acids and bile acid, resulting in systemic low-grade inflammation and insulin resistance.
Given the role of the gut microbiota on metabolic disorders, targeted probiotic formulations may be clinically relevant for optimizing metabolic health, influencing of insulin resistance and low-grade inflammation associated with early- and late-stage low-grade metabolic disorders, specifically T2DM.
